Abstract Purpose: The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), are involved in a wide range of biological activities, including cell proliferation, motility, invasion, and angiogenesis. The HGF/SF-Met signaling pathway is frequently activated in a variety of cancers, and uncontrolled Met activation correlates with highly invasive tumors and poor prognosis. In this study, we investigated the inhibitory effect of a novel soluble splice variant of Met on the HGF/SF-Met pathway. Experimental Design: Using our alternative splicing modeling platform LEADS, we have identified a novel splice variant of the Met receptor, which encodes a truncated soluble form of the receptor. This variant was produced as a recombinant Fc-fused protein named Cgen-241A and was tested in various cell-based assays representing different outcomes of the HGF/SF-Met pathway. Results: Cgen-241A significantly inhibited HGF/SF-induced Met phosphorylation as well as cell proliferation and survival. In addition, Cgen-241A showed a profound inhibitory effect on cell scattering, invasion, and urokinase up-regulation. The inhibitory effects of Cgen-241A were shown in multiple human and nonhuman cell types, representing different modes of Met activation. Furthermore, Cgen-241A showed direct binding to HGF/SF. Conclusions: Taken together, our results indicate that Cgen-241A is a potent antagonist of the HGF/SF-Met pathway, underlining its potential as a therapeutic agent for the treatment of a wide variety of human malignancies that are dependent on this pathway.
The Met oncogene encodes for the hepatocyte growth factor/ scatter factor (HGF/SF) tyrosine kinase receptor. Under physiologic conditions, the HGF/SF-Met pathway is essential for embryonic development, wound healing, and tissue regeneration (1, 2) . Met and HGF/SF are expressed in a wide variety of tissues. The expression of Met is normally confined to epithelial cells, whereas HGF/SF is produced by surrounding cells of mesenchymal origin (3) . The Met receptor is a heterodimer composed of an a-chain that encodes part of the extracellular domain (ECD) and a h-chain encompassing the remainder of the ectodomain, the transmembrane domain, and the cytoplasmic portion (1) . Binding of HGF/SF to the Met receptor induces receptor dimerization and phosphorylation on multiple tyrosine residues within the juxtamembrane, the catalytic core, and the cytoplasmic tail domains, thereby regulating receptor internalization, catalytic activity, and multisubstrate docking (4 -6) . The HGF/SF-Met pathway is involved in a wide range of biological processes including cell proliferation, survival, motility, invasion, angiogenesis, and morphogenic differentiation (1, 6) .
HGF/SF-Met signaling is involved in the promotion of the invasive/metastatic tumor phenotype through the induction of epithelial cell dissociation, scattering, motility, and invasion. The latter requires the degradation of the surrounding extracellular matrix, which is mediated by several proteolytic enzymes (5, 7) . HGF/SF stimulation has been shown to induce the expression of the serine protease urokinase (urokinase plasminogen activator) and its receptor (urokinase plasminogen activator receptor) in a variety of cell lines expressing Met. Most of the extracellular matrix -degrading properties of urokinase plasminogen activator are mediated through plasmin and the indirect activation of metalloproteinases, possessing potent extracellular matrix -degrading capabilities (8) .
Although HGF/SF-Met signaling plays a key role in normal development, inappropriate activation of this signaling pathway has been implicated in tumorigenesis and metastatic progression. Aberrant HGF/SF-Met signaling is a crucial feature of many human malignancies and contributes primarily to the growth, invasiveness, and metastasis of carcinomas and sarcomas (9 -11) . There are several mechanisms by which Met becomes dysregulated and hyperactivated in human cancers. HGF/SF produced in the surrounding stroma can activate Met in a paracrine manner, whereas HGF/SF expressed by the tumor cells may activate this pathway in an autocrine manner. Met activation can also occur through ligandindependent mechanisms, including Met mutations, and overexpression in the presence or absence of gene amplification, leading to constitutive receptor dimerization in the absence of ligand (1, 3, 6) .
In view of the critical role that the HGF/SF-Met pathway plays in cancer, various inhibitory strategies have been employed to therapeutically target this pathway and several candidates are currently under development. Three main approaches have been employed to selectively inhibit this pathway: antagonism of HGF/SF-Met interaction, inhibition of the tyrosine kinase catalytic activity of Met, and blockade of intracellular Meteffectors interactions (2, 7, 12 -14) . Among the current developments are neutralizing antibodies against HGF/SF (15 -17), antagonistic antibodies against Met (18, 19) , antagonistic fragment of HGF/SF (NK4; reviewed in ref. 20) , and small molecules that inhibit Met catalytic activity (21 -23) .
Here, we report the identification of Met-934, a novel splice variant encoding a truncated soluble form of Met, which contains part of the ECD, lacks the transmembrane and cytoplasmic domains and ends with a stretch of unique amino acid sequence. This splice variant was produced as a recombinant Fc-fused protein in mammalian cells and was designated Cgen-241A. The biological activity of Cgen-241A was assessed in various cell-based assays, reflecting different outcomes of Met activation. Cgen-241A inhibited HGF/SF-mediated Met phosphorylation, cell proliferation, scattering and invasion, and urokinase activation. In addition, Cgen-241A exhibited binding to cells overexpressing Met and promoted their apoptosis. This, together with the results showing direct binding of Cgen-241A to HGF/SF, alludes to several mechanisms of action. Our results indicate that Cgen-241A is a potent antagonist of the HGF/SF-Met pathway, suggesting a therapeutic potential.
Materials and Methods
Cell culture and reagents HT115 and MDCK-II (Madin-Darby canine kidney) cells were obtained from the European Collection of Cell Cultures. MDA-MB-231, AsPC1, H69, and HEK-293T cells were obtained from the American Type Culture Collection. MKN45 and SUIT-2 cells were obtained from the Japanese Collection of Research Bioresources. D1-DMBA-3 (DA3) cells were derived from poorly differentiated mammary adenocarcinoma using dimethylbenzanthracene (24) . All cell lines were cultured as recommended by the provider. Dulbecco's PBS (DPBS), heat-inactivated fetal bovine serum, RPMI 1640, and DMEM were purchased from Biological Industries (unless indicated otherwise).
Discovery and variant transcript evaluation
The discovery of Met-934, a novel Met splice variant, was carried out using LEADS, Compugen's alternative splicing modeling platform (described previously in refs. 25 -28) . The LEADS platform used expressed sequence tags from dbEST (GenBank version gb126, October 2001) and the human genome (build 27, October 28, 2001) to predict gene structure and splice variants by clustering and assembly procedures.
The existence of the Met splice variant transcript was verified by reverse transcription-PCR (RT-PCR) using RNA isolated from ES-2 cells as described in Supplementary Materials and Methods. For quantitative RT-PCR (qRT-PCR) analysis, we exploited a panel of cDNA samples obtained by reverse transcription on total RNA from ovarian tumor and normal samples using random hexamers. qRT-PCR was carried out with primers specific for the Met-934 transcript (derived from exons 11 and 12a; see Fig. 1A ) or with primers specific for the wild-type (WT) transcript (derived from exons 11 and 13; see Fig. 1A ). The RT and qRT-PCR analysis is described in detail in Supplementary Materials and Methods. The results were normalized based on the expression of several housekeeping genes, and the relative quantity of each specific amplicon (WT or Met-934) was calculated.
Protein production and purification of Cgen-241A The coding sequence of the Met-934 splice variant (accession no. EU176015) was cloned as a fusion to the Fc fragment of IgG1. The recombinant Fc-fused protein was designated Cgen-241A. The COOHterminal lysine of Met-934 was fused to the heavy-chain hinge of the Fc followed by the CH2 and CH3 regions. The open reading frame of the recombinant protein was codon optimized for high-level expression in mammalian cells. The optimized DNA sequence was synthetically synthesized by GeneArt with the addition of flanking DNA sequences corresponding to EcoRI and NotI restriction sites at the 5 ¶ and 3 ¶ ends of the DNA fragment, respectively. The expression vector was constructed by double digestion of the optimized DNA fragment with EcoRI and NotI followed by its ligation into pIRESpuro3 (Clontech Laboratories). The resulting construct was transfected into HEK-293T cells using the FuGENE 6 Transfection Reagent (Roche Diagnostics). After 48 h, transfected cells were subjected to antibiotic selection with 5 Ag/mL puromycin (Sigma-Aldrich). Stable pools were analyzed for protein secretion by SDS-PAGE.
Large-scale protein production was carried out in EX-CELL 293 serum-free medium (SAFC Biosciences) supplemented with 4 mmol/L glutamine in a stirred-tank bioreactor (Applikon) operated in perfusion mode. Harvested culture medium was concentrated f10-fold and filtered through a 0.22 Am filter. The Fc-fused protein, Cgen-241A, was purified by affinity chromatography on nProtein A Sepharose 4 Fast Flow (GE Healthcare) according to the manufacturer's recommendations and eluted with 100 mmol/L citrate-phosphate (pH 3.5). Fractions containing the protein (analyzed by SDS-PAGE) were pooled and dialyzed against DPBS. Mock preparation was produced by the same production and purification processes using HEK-293T cells transfected with an empty pIRESpuro vector.
Analysis of Cgen-241A protein by SDS-PAGE Purified Cgen-241A was analyzed by SDS-PAGE followed by staining with SimplyBlue SafeStain (Coomassie; Invitrogen). Western blot analysis for the Fc portion was carried out using peroxidase -conjugated goat anti-human IgG (Sigma-Aldrich). Analysis of the a-chain of Met was carried out with rabbit polyclonal antibodies (custom made by Sigma; Sigma-Aldrich) followed by peroxidase-conjugated goat antirabbit IgG (Jackson ImmunoResearch Laboratories).
Functional cell assays
Met phosphorylation assay. MDA-MB-231, SUIT-2, and HT115 cells were seeded in growth medium at 3 Â 10 5 per well in six-well plates. After 24 h, the cells were washed once and then grown in serum-free medium for 3 days. At the day of stimulation, Cgen-241A, or the equivalent mock preparation, was added to the cells in serum-free medium for 1 h. Stimulation was done by adding recombinant human HGF (R&D Systems) for 10 min. Cells were then washed twice with ice-cold DPBS, and cell extracts were prepared with buffer containing 50 mmol/L Tris (pH 7.4), 1% NP-40, 2 mmol/L EDTA, and 100 mmol/L NaCl supplemented with complete protease inhibitor cocktail (Roche Diagnostics) and phosphatase inhibitor cocktails 1 and 2 (SigmaAldrich). H69 cells, which are propagated in suspension, were grown for 3 days in medium without serum. At the day of stimulation, 5 Â 10 5 cells were transferred to 24-well plates. Cgen-241A was added to the cells in serum-free medium for 1 h. Subsequently, cells were incubated with HGF/SF for 10 min and cell extracts were prepared as described above.
Cell extracts were separated on 4% to 12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membranes (Schleicher & Schuell; Whatman). Immunoblotting was carried out with rabbit polyclonal anti-phospho-Met (pY1230/pY1234/pY1235 phosphospecific antibody; Biosource International) and peroxidase-conjugated goat antirabbit IgG according to the manufacturer's instructions. SuperSignal West Pico Chemiluminescent (Pierce) was used for detection of horseradish peroxidase. Membranes were stripped with 62.5 mmol/L Tris-HCl (pH 6.7), 100 mmol/L h-mercaptoethanol, and 2% SDS for 15 min at 50jC and reprobed with rabbit polyclonal anti-Met (C-12; Santa Cruz Biotechnology). The autoradiograms, with band signals at nonsaturating exposures, were scanned and measured by densitometry using ImageJ 1.36b (NIH) software.
Proliferation assay. Proliferation was evaluated by assessment of bromodeoxyuridine (BrdUrd) incorporation. AsPC-1 cells were seeded in a 96-well plate at 8 Â 10 3 per well. The following day, cells were rinsed and incubated for 48 h in medium containing 0.1% heatinactivated fetal bovine serum. Cgen-241A or mock preparation was then added to the cells, and after 1 h, 5 ng/mL HGF/SF was added and the cells were incubated overnight with BrdUrd. Incorporation of BrdUrd into newly synthesized DNA was assessed using a colorimetric immunoassay kit, Cell Proliferation ELISA, BrdUrd (Roche Diagnostics). Absorbance was measured at 370 nm (reference wavelength, 492 nm). Statistical significance was determined by t test.
Apoptosis assay. MKN45 or AsPC1 cells were seeded in 96-well plates at 8 Â 10 3 per well and cultured overnight. The medium was then replaced with medium containing 0.1% heat-inactivated fetal bovine serum. After additional 24 h, Cgen-241A or equivalent mock preparation was added to the cells. Apoptosis was analyzed after 24 h (AsPC1) or 48 h (MKN45) using the Cell Death Detection ELISA PLUS kit (Roche Diagnostics), detecting histone-complexed DNA fragments, according to the manufacturer's instructions. Statistical significance was determined by t test.
Scattering assay. MDCK-II cells were seeded in 96-well plates at 1.5 Â 10 3 per well. After 24 h, 5 ng/mL HGF/SF and Cgen-241A or mock preparation were added to the cells in assay medium. After an additional 48 h, the cells were examined under a microscope (Olympus CKX41, Olympus America) and a score of 1 to 5 was given to evaluate minimal up to maximal scattering activity in the absence or presence of HGF/SF, respectively. Original magnification was Â10. Images were acquired using a CFW-1310C camera (Scion) and Scion VisiCapture (Scion).
Invasion assay. Invasion assays were done as previously described by Albini et al. (29) in 96-well chemotaxis chambers (NeuroProbe). Lower and upper wells were separated by Nucleopore filters (5 Am pore size) coated with Matrigel (3.6 Ag/mm 2 ; BD Biosciences). The human HGF/SF used in this experiment was purified from the supernatant of transformed NIH3T3 cells engineered to overexpress HGF/SF as described previously (30) . Cgen-241A or mock preparation were diluted in DMEM (Invitrogen/Life Technologies) containing 100 ng/mL HGF/SF, supplemented with 1 mg/mL bovine serum albumin, and added to the lower wells in triplicates. DA3 cells were seeded in the upper wells at 4 Â 10 4 per well in DMEM and allowed to invade to lower wells by chemotaxis during a 48-h period. Noninvading cells remaining on the upper surface of the filter were removed with a cotton swab. Invading cells that migrated to the lower surface were fixed with cold methanol and stained with Giemsa (Sigma-Aldrich). The stained filter was scanned and the area occupied by stained cells was analyzed by Photoshop software version 7.1. Statistical significance was determined by t test.
Urokinase activity assay. Urokinase activity assays were done as described previously by Webb et al. (31) . MDCK-II or SUIT-2 cells were seeded in 96-well plates at 1.5 Â 10 3 or 2.5 Â 10 3 per well, respectively. The following day, 10 ng/mL HGF/SF and Cgen-241A or mock preparation were added in assay medium. The cells were incubated at 37jC for additional 24 h. Cells were then washed twice with DMEM (without phenol red; Invitrogen/Life Technologies or Biological Industries), and 200 AL reaction buffer [50% (v/v) 0.05 units/mL plasminogen (Roche Diagnostics) in DMEM (without phenol red), 40% (v/v) 50 mmol/L Tris (pH 8.2), and 10% (v/v) 3 mmol/L Chromozyme PL (Roche Diagnostics) in 100 mmol/L glycine solution] was added. The plate was incubated at 37jC for 4 h, after which absorbance was measured at a single wavelength of 405 nm. Statistical significance was determined by t test.
Binding studies
Surface plasmon resonance analysis. Surface plasmon resonance analysis was done by a BIAcore 3000 biosensor (BIAcore). Briefly, 10 Ag/mL HGF/SF in acetate buffer (pH 5) was immobilized onto a research grade CM5 BIAcore sensorchip to a level of %300 resonance units using the BIAcore standard amine coupling procedure. The chip was activated by coupling reagent and suppressed by 70 AL of 1 mol/L ethanol amine (10 AL/min) for the detection of nonspecific binding to the chip surface. Cgen-241A and Met(ECD)-Fc [recombinant human HGF receptor (c-MET)/Fc chimera; R&D Systems], diluted in DPBS supplemented with 200 mmol/L NaCl, were injected at a flow rate of 20 AL/min for 2 to 3 min and allowed to dissociate for 3 min. In cases where there was a need for regeneration, this was carried out by injection of 100 AL of 10 mmol/L NaOH at a flow rate of 10 AL/min. The chip design included flow cell-1, which served as control, and flow cell-2, which was immobilized with HGF/SF. Results are presented as resonance units of flow cell-2 after subtraction of the control flow cell (flow cell-1). Binding specificity was confirmed by preincubation of Cgen-241A with HGF/SF at a 1:5 molar ratio. Binding affinities were determined using a 1:1 Langmuir model (BIA Evaluation software version 4.1; BIAcore).
Flow cytometry. MKN45 cells grown to near confluence were rinsed twice with sterile DPBS and detached from the flask following 5-min incubation at 37jC with 1.5 mL nonenzymatic cell dissociation buffer (Invitrogen/Life Technologies). Cells (1.5 Â 10 5 ) were incubated with Cgen-241A, CD200-Fc, or control (no protein) in 50 AL DPBS in triplicates for 1 h at 4jC. Cells were then washed with 1 mL cold fluorescence-activated cell sorting buffer (DPBS containing 0.1% bovine serum albumin and 0.05% sodium azide) and cell pellets were resuspended in 100 AL fluorescence-activated cell sorting buffer containing R-phycoerythrin -conjugated F(ab ¶) 2 fragment goat antihuman IgG (Jackson ImmunoResearch Laboratories) for 45 min at 4jC. Cells were subsequently washed with 1 mL cold fluorescence-activated cell sorting buffer and resuspended in 250 AL of the same buffer. Acquisition and data analysis were conducted on FACSCalibur platform using the CellQuest Pro program (Becton Dickinson). For competitive binding assay, Cgen-241A was preincubated for 15 min with HGF/SF at a 10:1 molar ratio, before its addition to the cells, and the binding was detected as described above. Statistical significance was determined by t test.
Results
Discovery and experimental evaluation of Met-934 and production of its Fc-fused recombinant protein, Cgen-241A. We have discovered a novel Met splice variant using LEADS, Compugen's alternative splicing modeling platform (as described in Materials and Methods). This splice variant, named Met-934, is composed of the first 12 exons of the MET gene followed by an extension of the 12th exon (Fig. 1A) . This splicing event introduces a stop codon upstream to the transmembrane domain, leading to the formation of a soluble receptor variant, 934 amino acids in length, which maintains 910 amino acids of the Met ECD and possesses a unique COOH-terminal tail of 24 amino acids (Fig. 1B) . The existence of this splicing event was supported by a large number of reliable expressed sequence tags from different library sources. The natural existence of this splice variant was verified by RT-PCR using RNA isolated from the human ovarian clear cell carcinoma ES-2 cell line (data not shown). qRT-PCR analysis was carried out as described in Materials and Methods using a panel of normal and tumor ovarian samples to determine the relative expression of the WT and the Met-934 transcripts. Figure 1C depicts the ratio of the relative expression of WT versus Met-934 transcripts in each sample. The results indicate that the ratio of WT versus variant expression in tumor samples (average, 29.7) is considerably higher than that in normal samples (average, 11.7). Furthermore, whereas the WT transcript was highly overexpressed (51% of tumor samples show >10-fold overexpression in tumors compared with normal samples, with a median of 10-fold; Supplementary Fig. S1A ), the Met-934 transcript displays only moderate overexpression (11% of tumor samples show >10-fold overexpression, with a median of 3-fold; Supplementary Fig. S1B ). Taken together, our results indicate a reduction in the relative expression of Met-934 compared with WT in ovarian tumors.
The endogenous expression of the protein resulting from this splice variant was not examined. We focused on the potential usage of this splice variant as a therapeutic candidate. Met-934 variant was cloned as a fusion to the Fc portion of human IgG1 to increase its stability. The recombinant Fc-fused protein was produced in a mammalian expression system and was designated Cgen-241A. Figure 1D shows Cgen-241A protein produced and purified from HEK-293T cells. The Coomassie staining shows the expected unprocessed precursor Fig. 1 . Met-934 splice variant structure and evaluation and production of the recombinant Cgen-241A protein. A, schematic presentation of mRNA (white boxes) and protein (gray boxes) of Met-934 splice variant compared with theWT Met receptor. Exons 1to 12 encode for the ECD, spanning the Sema domain, PSI domain, and IPTrepeats. Exon 13 encodes for the transmembrane domain. Exons 14 to 21encode for the intracellular domain including the juxtamembrane and tyrosine kinase domains. Met-934 mRNA contains the first 12 exons followed by an exon extension (exon 12a), which introduces a stop codon upstream to the transmembrane domain, and encodes a unique 24^amino acid tail (black boxes, exon 12a and the unique tail). B, amino acid sequence of Met-934 splice variant. The functional domains are indicated above the sequence. Bold letters, 24^amino acid unique tail of the splice variant. The sequence encoding human IgG1Fc was fused to the COOH-terminal Lys 934 of Met-934 variant to produce the recombinant Cgen-241A protein.
(a-and h-chains) fused to Fc (f170 kDa) as well as the mature a-chain of Met (f50 kDa) and h-chain fused to Fc (f120 kDa; see, for example, ref. 31). These were further identified by immunoblotting with anti-Met (a-chain-specific) antibodies and anti-human IgG (Fc-specific) antibodies.
Inhibition of HGF/SF-induced Met phosphorylation by Cgen-241A. To study the effect of Cgen-241A on the HGF/SF-Met pathway, we tested its ability to inhibit HGF/SF-induced phosphorylation of the Met receptor. MDA-MB-231 (human breast adenocarcinoma), HT115 (colon carcinoma), H69 (small cell lung carcinoma), and SUIT-2 (human pancreatic cancer established from liver metastasis) cells, all known to express Met and to respond to HGF/SF induction (32 -36), were serum starved and treated with different concentrations of Cgen-241A before stimulation with HGF/SF. Met phosphorylation levels were measured using a phosphospecific antibody, which recognizes three specific tyrosines (Y1230, Y1234, and Y1235) that are located within the Met tyrosine kinase domain and are known targets of autophosphorylation on activation (5). Blots were reprobed with a general anti-Met antibody, and the phosphorylation levels were normalized to total Met protein levels. As shown in Fig. 2 , Cgen-241A strongly inhibited HGF/SF-induced Met-phosphorylation in these cell lines in a dose-dependent manner. Over 50% inhibition was obtained in MDA-MB-231 cells with as little as 3 nmol/L, and up to 84% inhibition with 100 nmol/L Cgen-241A, whereas the mock preparation did not show any inhibitory activity ( Fig. 2A) . Similar results were obtained with HT115, H69, and SUIT-2 cells (Fig. 2B-D, respectively) . These results indicate that Cgen-241A inhibits HGF/SF-induced Met activation.
Cgen-241A inhibits HGF/SF-induced proliferation and promotes apoptosis in the absence of HGF/SF. We next analyzed the effects of Cgen-241A on cell proliferation using AsPC1 (human pancreatic adenocarcinoma) cells, which express high levels of Met (33) . Cells were serum starved and subsequently treated with different concentrations of Cgen-241A before HGF/ SF stimulation. As shown in Fig. 3A , Cgen-241A dramatically inhibited HGF/SF-induced proliferation measured by BrdUrd incorporation in a dose-dependent manner, reaching up to 95% inhibition with 30 nmol/L. The mock preparation had practically no effect on HGF/SF-induced proliferation in these cells. These results point to a strong antiproliferative activity of Cgen-241A.
The ability of Cgen-241A to induce apoptosis was evaluated using the human gastric carcinoma cell line, MKN45. These cells are marked by high-level amplification of the MET gene, resulting in overexpression of Met and constitutive activation of this pathway, providing survival signals to these cells (37) . Accordingly, inhibition of Met kinase activity has been shown to induce apoptosis in MKN45 cells as well as the GTL-16 cell line derived from them (21, 37, 38) . As shown in Fig. 3B , treatment of MKN45 cells with 100 nmol/L Cgen-241A increased the level of apoptosis by 75%, whereas the mock preparation had no effect. Induction of apoptosis was also assessed in AsPC1 cells, which also express high levels of Met (33) . In these cells, 30 nmol/L Cgen-241A was sufficient to induce a 71% increase in the level of apoptosis. All together, these results indicate a strong antimitogenic activity of Cgen-241A.
Inhibition of HGF/SF-induced motility and invasion by Cgen-241A. Induction of the HGF/SF-Met pathway is known to increase cell motility and invasiveness, which contributes to the metastatic characteristics of malignant cells. It is well documented that MDCK-II cells, which normally grow in clusters, exhibit disruption and scattering of cell colonies on HGF/SF treatment (16, 21, 39, 40) . These cells were used to determine the effect of Cgen-241A on HGF/SF-induced cell scattering. MDCK-II cells were treated with different concentrations of Cgen-241A in the presence of HGF/SF and cell scattering was evaluated by a scoring system as described in Materials and Methods. As shown in Fig. 4A , MDCK-II cells grew in tight clusters, whereas treatment with HGF/SF induced cell dissociation and scattering. Cgen-241A dramatically inhibited HGF/SF-induced scattering of MDCK-II cells in a dosedependent manner, reaching >90% inhibition at 100 nmol/L, whereas the mock preparation had no effect (Fig. 4B) . Similar results were obtained in HT115 cells (data not shown). To examine the effect of Cgen-241A on cell invasion, we used DA3 cells, which are derived from a mouse mammary carcinoma. It has been shown previously that HGF/SF induces invasion of these cells, whereas inhibition of HGF/SF-Met pathway reduces this effect (24) . HGF/SF and different concentrations of Cgen-241A were placed in the lower wells of a chemotaxis chamber, while DA3 cells were placed in the upper wells and allowed to invade to the lower wells through a Matrigel-coated filter. Results show that DA3 cells migrated in response to HGF/SF (defined as 100% invasion), whereas very low spontaneous migration was detected in the absence of HGF/SF (Fig. 5A) . Cgen-241A strongly inhibited HGF/SF-induced cell invasion at all doses, whereas the mock preparation had no effect.
Cell invasion not only requires cell motility but also the degradation of the surrounding extracellular matrix, mediated by several proteolytic enzymes, one of which is the serine protease urokinase (5, 7, 41) . To test the effect of Cgen-241A on HGF/SF-induced urokinase up-regulation, MDCK-II cells, shown previously to possess high urokinase activity (31) , and SUIT-2 cells were treated with different concentrations of Cgen-241A in the presence of HGF/SF. Figure 5B shows that Cgen-241A inhibited HGF/SF-induced urokinase activity in MDCK-II cells in a dose-dependent manner, reaching 97% inhibition at 10 nmol/L, with an IC 50 of f2 nmol/L. The mock had no significant effect. Comparable results were obtained with the SUIT-2 cell line (Fig. 5C) , exhibiting a maximal effect (84% inhibition) at 10 nmol/L Cgen-241A. Cell growth was practically not affected in MDCK-II and SUIT-2 cells under these conditions (data not shown). Similar results were also obtained in the human leiomyosarcoma cell line SK-LMS-1 (data not shown). The inhibition of urokinase up-regulation by Cgen-241A at nanomolar concentration values is of particular importance because the activity of this protease facilitates cell invasion, tumor progression, and promotion of metastases. , statistically significant. B, induction of apoptosis by Cgen-241A in MKN45 cells. Cells were treated with the indicated concentrations of Cgen-241A or mock preparation. Relative apoptosis (mean F SD) compared with untreated cells was measured after 48 h using a quantitative determination of cytoplasmic histone-associated DNA fragments. *, P < 0.0002, statistically significant. C, induction of apoptosis by Cgen-241A in AsPC1cells.
As in B, except that relative apoptosis was measured after 24 h. *, P < 0.005, statistically significant. These results, together with those of the scattering and invasion assays described above, indicate an antitumorigenic and antimetastatic potential of Cgen-241A.
Binding properties of Cgen-241A. The direct binding of Cgen-241A to HGF/SF was examined using the SPR-BIAcore platform. The sensograms revealed an association constant (k a ) of 1. (Fig. 6A ). This binding affinity was comparable with that of a commercial Met(ECD)-Fc fused protein (data not shown). In addition, preincubation of Cgen-241A with HGF/SF (at a 1:5 molar ratio) completely abolished the interaction between Cgen-241A and immobilized HGF/SF, indicating that the binding was specific (data not shown). These findings suggest that Cgen-241A may act by sequestering HGF/SF, thus preventing its interaction with the Met receptor on the cell surface.
As shown previously Cgen-241A was able to induce apoptosis of Met-overexpressing cells, MKN45, possibly by interference with receptor dimerization and subsequent activation, leading to the inhibition of survival signals provided by this pathway. Based on this assumption, we tested the ability of Cgen-241A to directly interact with these cells. MKN45 cells were incubated with different concentrations of Cgen-241A and the binding of Cgen-241A to the cells was evaluated by flow cytometry. Results shown in Fig. 6B and C indicate that Cgen-241A binds to MKN45 cells in a dose-dependent manner with a 4.5-to 5-fold increase in fluorescence signal intensity at 300 nmol/L. CD200-Fc, a nonrelevant protein fused to Fc, displayed fluorescence signal intensity similar to the background levels obtained in the absence of Cgen-241A. Preincubation of Cgen-241A with HGF/SF, before addition to the cell suspension, resulted in a 50% inhibition of Cgen-241A binding to the cells (Fig. 6C) . This inhibition was specific because the addition of HGF/SF to the control CD200-Fc protein had no effect.
Taken together, these results show that Cgen-241A binds HGF/SF and imply that it may also bind the Met receptor, suggesting alternative inhibitory mechanisms of the HGF/SFMet pathway.
Discussion
In this study, we describe the discovery of a novel soluble splice variant of the Met tyrosine kinase receptor (Met-934) and the characterization of its recombinant Fc-fused form, Cgen-241A. We have shown that Cgen-241A reduces HGF/SFinduced Met phosphorylation as well as cell proliferation and survival, indicating antimitogenic activity. In addition, Cgen-241A inhibits properties related to cell motility and invasiveness shown by inhibition of cell scattering, cell invasion, and urokinase activity. Taken together, our results indicate that Cgen-241A possess potent anti-Met antagonistic activity and suggest antitumorigenic and antimetastatic activities of this protein.
The direct binding of Cgen-241A to HGF/SF, shown by the BIAcore studies, and the inhibition of HGF/SF-dependent activities suggest that Cgen-241A exerts its effect by competing with the membrane-bound Met receptor for its ligand through HGF/SF sequestration, thus preventing HGF/SF from activating Met and its downstream signaling pathway. The induction of apoptosis in MKN45 and AsPC1 cells in the absence of HGF/SF, together with our data showing that Cgen-241A binds to Metoverexpressing MKN45 cells, insinuate that Cgen-241A may also exert its effect via direct interaction with the membranal Met receptor. Thus, alternatively, Cgen-241A may inhibit Met activation through its down-regulation by inducing its internalization and subsequent degradation or directly by interfering with its dimerization (42) .
In support of our results, previous studies have shown that a recombinant Sema protein (rSema), composed of the NH 2 -terminal Met Sema domain, is responsible for HGF/SF binding and receptor dimerization and can block ligand-dependent and ligand-independent Met-related cellular activities (43, 44) . In addition, Decoy Met (a soluble protein consisting of the complete ECD) was also shown to block ligand-dependent and ligand-independent Met activation (45, 46) and its administration as a transduced lentiviral vector was shown to inhibit tumor growth, metastasis, and angiogenesis in vivo (46) . As opposed to Decoy Met, Cgen-241A is a natural splice variant, which may serve a physiologic role, and is therefore expected to provide a therapeutic advantage. In addition, its fusion to IgG1 Fc is expected to confer a longer half-life in vivo. The potential therapeutic effect of Cgen-241A will be tested in future studies.
Several alternative splice variants of Met were identified over the years (47 -49) ; however, none of the published isoforms encode a truncated secreted protein. Our splice variant, Met-934, is therefore unique, as it encodes a soluble truncated Met variant, which lacks the transmembrane and cytoplasmic domains of Met. Alternative splicing is one of the mechanisms that can generate soluble receptors. Various examples are known in the literature, mainly of class I and II cytokine receptors, interleukin-1 receptor, transforming growth factor-h receptor, and tumor necrosis factor receptor, as well as receptors such as vascular endothelial growth factor receptor (50) . The regulatory function of these soluble receptors, which may function as decoy receptors, is well established. The endogenous Met-934 splice variant might possess an antagonistic activity, therefore playing a physiologic role in the regulation of the HGF/SF-Met pathway. In support of this assumption, our qRT-PCR results show a reduction in Met-934 expression relative to WT in ovarian tumor samples.
In recent years, there has been extensive evidence that Met signaling is involved in tumor progression and promotion of metastases of many human cancers, and the understanding of its molecular basis has been greatly improved. The development of a variety of HGF/SF-Met antagonists with clinical potential has increased dramatically and many approaches have been taken in an attempt to inhibit HGF/SF or Met in multiple experimental systems (3, 13) . Met is often activated in human cancers by different modes. Activation of Met in cancers such as osteosarcomas and glioblastoma, which express both Met and HGF/SF, occurs most often in an autocrine manner through a ligand-dependent mechanism, whereas in breast, prostate, and lung cancers, it is believed to be paracrine, in which HGF/SF is expressed by the stroma cells surrounding the tumor (4). In many carcinomas, Met activation occurs through a ligandindependent mechanism by mutation or overexpression of the receptor by the tumor cells (1) .
As we have shown in this study, Cgen-241A has a profound inhibitory effect on the HGF/SF-Met pathway. Its natural existence, together with its unique properties, may provide an advantage as an anticancer therapeutic agent. The therapeutic potential of Cgen-241A should be further analyzed in xenograft human cancer models, representing different modes of Met activation and clinical indications.
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